Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.

Autor: Boissel L; Molecular Oncology Research Institute; Tufts Medical Center; Boston, MA USA., Betancur-Boissel M; Molecular Oncology Research Institute; Tufts Medical Center; Boston, MA USA., Lu W; Molecular Oncology Research Institute; Tufts Medical Center; Boston, MA USA ; Division of Hematology/Oncology; Tufts Medical Center; Boston, MA USA., Krause DS; Center for Regenerative Medicine and Cancer Center; Massachusetts General Hospital; Boston, MA USA., Van Etten RA; Molecular Oncology Research Institute; Tufts Medical Center; Boston, MA USA ; Division of Hematology/Oncology; Tufts Medical Center; Boston, MA USA., Wels WS; Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus; Frankfurt am Main, Germany., Klingemann H; Molecular Oncology Research Institute; Tufts Medical Center; Boston, MA USA ; Division of Hematology/Oncology; Tufts Medical Center; Boston, MA USA.

Publikováno v: Oncoimmunology [Oncoimmunology] 2013 Oct 01; Vol. 2 (10), pp. e26527. Date of Electronic Publication: 2013 Oct 22.